Mylan (MYL) Comments on Unfavorable Copaxone Ruling; Reaffirms Expectations for No EPS Impact

Article Stock Quotes (1) Comments (0)

Mylan Inc. (Nasdaq: MYL) has commented on an unfavorable ruling issued by the U.S. District Court for the Southern District of New York in relation to Teva's patent infringement lawsuit against Mylan in relation to Mylan's proposed generic version of Copaxone.

Mylan CEO Heather Bresch commented: "Although Mylan is disappointed in the Court's decision, and while we have not yet had the opportunity to review the Court's opinion, we fully intend to evaluate our options for an appeal once the Court's full opinion becomes available.

"Importantly and as previously stated, Mylan's earnings guidance for 2012 and earnings targets for 2013 are not reliant on the launch of a generic Copaxone, and therefore our expectations for these periods are unchanged."

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Mylan (MYL) Launches Generic Tricor Tabs (ABBV)
• Best Buy (BBY) Posts Q1 adj.-EPS of 32c; Comps Down 1.1%
• Sanofi (SNY), Regeneron (REGN) Report Publication of Positive Dupilumab Phase 2a Data

Create E-mail Alert Related Categories

Corporate News, FDA

Related Entities

Earnings

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?